Plazomitsin
Plazomitsin
| |
| Sistematik (IUPAC) nomi | |
| ? | |
| Identifikatorlar | |
| CAS raqami | ? |
| ATK kodi | ? |
| PubChem | |
| DrugBank | |
| Kimyoviy maʼlumot | |
| Formulasi | C25H48N6O10 |
| Mol. massasi | ? |
| SMILES | izlash: , |
| Farmakokinetik maʼlumot | |
| Biofoydalilik | ? |
| Metabolizm | ? |
| Yar. parch. davri | ? |
| Ekskretsiya | ? |
| Terapevtik tavsiyalar | |
| Licence data |
|
| Homiladorlik kat. |
? |
| Qonuniy statusi | |
| Qabul qilish | ? |
Zemdri brendi ostida sotiladigan plazomitsin siydik yo'llarining infektsiyalarini davolashda qo'llaniladigan aminoglikozid antibiotikidir[1]. 2019-yilda aniq varianti bo'lmaganlar uchun tavsiya etilgan[1]. Vena ichiga in'ektsiya yo'li bilan yuboriladi[1].
Umumiy nojo'ya ta'sirlar orasida buyrak muammolari, diareya, ko'ngil aynishi va qon bosimining o'zgarishi kiradi[1] .Boshqa jiddiy qo' shimcha ta'sirlar orasida eshitish qobiliyatining yo'qolishi, Clostridium difficile bakteriyasi bilan bog'liq diareya, anafilaksiya va muskullarl kuchsizligi ham bor. Homiladorlik paytida foydalanish chaqaloqqa zarar yetkazishi mumkin[1] .Plazomitsin bakteriyalarning oqsil hosil qilish qobiliyatini kamaytirishi orqali ishlaydi.[1]
Plazomitsin 2018-yilda Qo'shma Shtatlarda tibbiy foydalanish uchun tasdiqlangan[2][3] .U Jahon sog'liqni saqlash tashkilotining asosiy dorilar ro'yxatiga kiritilgan[4].
Tibbiyotda foydalanilishi[tahrir | manbasini tahrirlash]
Plazomitsin AQSh oziq-ovqat va farmatsevtika idorasi tomonidan davolash imkoniyatlari cheklangan yoki umuman mavjud bo'lmagan bemorlarda Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis yoki Enterobacter cloacae bakteriyalari sabab bo'luvchi pyelonefritni o'z ichiga olgan murakkab siydik yo'llari infektsiyalari kasalligi bo'lgan kattalar uchun tavfsiya etiladi. Zemdri tomir ichiga yuboriladigan infuzion bo'lib, kuniga bir marta yuboriladi[5][6][7].Ko'rsatigan samaradorlikning yo'qligi sababli qon oqimi infektsiyalarini davolash uchun ruxsat rad etilgan[2].Ko'rsatilgan samaradorlikning yo'qligi antibiotik samarasizligi bilan bog'liq emas, balki tadqiqotga kirish darajasi past edi. Sichqoncha modellari yordamida olib borilayotgan tadqiqotlar tirik qolishning yuqori darajasini belgiladi[8].
Plazomitsin daptomitsin yoki seftobiprole bilan metitsillinga chidamli Staphylococcus aureus, vankomitsinga chidamli S. aureus va Pseudomonas aeruginosa ga qarshi sefepim, doripenemitsillin yoki doripenem piperaz bilan biog'langanda hujayra ichiga sinergik faollikni ko'rsatishi haqida xabar berilgan[9]. Shuningdek, u karbapenemga chidamli Acinetobacter baumannii bakteriyasiga nisbatan kuchli hujayra ichi faolligini ko'rsatadi[10]. Plazomitsin meropenemdan kam emasligi aniqlandi [11].
Tarixi[tahrir | manbasini tahrirlash]
Preparat Achaogen biotexnologik kompaniyasi tomonidan ishlab chiqarilgan. 2012-yilda AQSh oziq-ovqat va farmatsevtika idorasi plazomitsinni ishlab chiqish va tartibga solishni tekshirish uchun tezkor belgini bergan[12] .2018 yilda plazomitsinni 2018 yilda murakkab UTI kasalligi bilan kasallangan va davolanish imkoniyatlari cheklangan yoki umuman bo'lmagan kattalar uchun tasdiqlangan[5]. Achaogen dori uchun mustahkam bozor topilmadi va bir necha oydan keyin bankrotlik e'lon qilindi[13] .Umumiy versiya Cipla USA tomonidan ishlab chiqarilgan[14].
Sintezlanilishi[tahrir | manbasini tahrirlash]
U sisomisindan gidroksi-aminobutirik kislota o'rnini 1-pozitsiyada va gidroksietil o'rnini 6 holatida qo'shish orqali sintezlanadi[15][9]. Ikkinchisi uning eng keng tarqalgan aminoglikozid atsetiltransferaza 6'-N- tip Ib (AAC(6')-Ib) tomonidan deaktivatsiyaga chidamli qiladi[16].
Nomlanishi[tahrir | manbasini tahrirlash]
Plazomitsin xalqaro nodavlat nomi (INN)[17].
Manbalar[tahrir | manbasini tahrirlash]
- ↑ 1,0 1,1 1,2 1,3 1,4 1,5 „Plazomicin Sulfate Monograph for Professionals“. Drugs.com. American Society of Health-System Pharmacists. Qaraldi: 2019-yil 10-oktyabr.
- ↑ 2,0 2,1 „FDA Approved Drug Products: Zemdri“. U.S. Food and Drug Administration. Qaraldi: 2018-yil 28-iyun.
- ↑ „Drug Approval Package: Zemdri (plazomicin)“. U.S. Food and Drug Administration (2018-yil 5-iyul). Qaraldi: 2019-yil 25-dekabr.
- ↑ . World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization, 2019. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ↑ 5,0 5,1 „Zemdri (plazomicin)- plazomicin injection“. DailyMed (2020-yil 30-iyul). Qaraldi: 2020-yil 11-oktyabr.
- ↑ „plazomicin (Rx)“. Medscape. Qaraldi: 2019-yil 14-sentyabr.
- ↑ Brown. „FDA Panel Recommends Plazomicin for cUTI but Not BSI“. Medscape (2018-yil 3-may). Qaraldi: 2019-yil 14-sentyabr.
- ↑ https://www.fda.gov/media/113289/download
- ↑ 9,0 9,1 "Comparison of the Next-Generation Aminoglycoside Plazomicin to Gentamicin, Tobramycin and Amikacin". Expert Review of Anti-Infective Therapy 10 (4): 459–73. April 2012. doi:10.1586/eri.12.25. PMID 22512755.
- ↑ "Can Plazomicin Alone or in Combination Be a Therapeutic Option against Carbapenem-Resistant Acinetobacter baumannii?". Antimicrob Agents Chemother 59 (10): 5959–66. October 2015. doi:10.1128/AAC.00873-15. PMID 26169398. PMC 4576036. //www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4576036.
- ↑ "Once-Daily Plazomicin for Complicated Urinary Tract Infections". New England Journal of Medicine 380 (8): 729–740. 21 February 2019. doi:10.1056/nejmoa1801467. ISSN 0028-4793. PMID 30786187.
- ↑ Achaogen, Inc. (2015-yil 8-yanvar). „Achaogen Announces Plazomicin Granted QIDP Designation by FDA“. Press-reliz.
- ↑ Jacobs, Andrew. „Crisis Looms in Antibiotics as Drug Makers Go Bankrupt“. The New York Times (2019-yil 25-dekabr).
- ↑ „Generic Zemdri Availability“ (en). Drugs.com. Qaraldi: 2019-yil 26-dekabr.
- ↑ "Synthesis and Spectrum of the Neoglycoside ACHN-490". Antimicrob Agents Chemother 54 (11): 4636–4642. November 2010. doi:10.1128/AAC.00572-10. PMID 20805391. PMC 2976124. //www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2976124.
- ↑ Cox, Georgina; Ejim, Linda; Stogios, Peter J.; Koteva, Kalinka; Bordeleau, Emily; Evdokimova, Elena; Sieron, Arthur O.; Savchenko, Alexei et al. (8 June 2018). "Plazomicin Retains Antibiotic Activity against Most Aminoglycoside Modifying Enzymes". ACS Infectious Diseases 4 (6): 980–987. doi:10.1021/acsinfecdis.8b00001. PMID 29634241. PMC 6167752. //www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=6167752.
- ↑ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 68". WHO Drug Information (World Health Organization) 26 (3): 314. September 2012. Archived from the original on 2 October 2014. https://web.archive.org/web/20141002045030/http://www.who.int/medicines/publications/druginformation/issues/DrugInformation2012_Vol26-3/en/. Qaraldi: 27 April 2016.Plazomitsin]]
Qo'shimcha adabiyotlar[tahrir | manbasini tahrirlash]
- „FDA Briefing Information for the May 2, 2018 Meeting of the Antimicrobial Drugs Advisory Committee“ (PDF). U.S. Food and Drug Administration (2018-yil 2-may). Qaraldi: 2019-yil 14-sentyabr.
- „Achaogen Briefing Information for the May 2, 2018 Meeting of the Antimicrobial Drugs Advisory Committee“ (PDF). U.S. Food and Drug Administration (2018-yil 2-may). Qaraldi: 2019-yil 14-sentyabr.
- „Errata to the Achaogen Briefing Information for the May 2, 2018 Meeting of the Antimicrobial Drugs Advisory Committee“ (PDF). U.S. Food and Drug Administration (2018-yil 2-may). Qaraldi: 2019-yil 14-sentyabr.
Havolalar[tahrir | manbasini tahrirlash]
- „Plazomicin“. Drug Information Portal. U.S. National Library of Medicine.
- „Plazomicin sulfate“. Drug Information Portal. U.S. National Library of Medicine.